Inotuzumab ozogamicin

About

Therapy type: Targeted therapy

Therapy strategy: BCR-ABL inhibition

Mappings

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Organization(s) Biomarker(s) Cancer type Therapy(ies)
EMA (1) FDA (1) CD22 + Acute Lymphoid Leukemia Inotuzumab ozogamicin
EMA (1) BCR::ABL1, CD22 + Acute Lymphoid Leukemia Inotuzumab ozogamicin